Do Inflammatory and Nutritional Markers Predict Prognosis in Metastatic Non-Small Cell Lung Cancer Patients Receiving Nivolumab
Journal of Inflammation Research · 2025-11 · Volume 18 · 15283-15292
DOI: 10.2147/jir.s541842 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Inflammation Research, 2025-11. Verfasst von Esra Zeynelgil und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Ankara Etlik City Hospital, Ankara, Turkey. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Objective
To investigate the prognostic value of clinical and inflammatory markers predicting response to nivolumab in patients with metastatic non-small cell lung cancer (NSCLC). Materials and Methods: Clinical, demographic and laboratory data of stage 4 NSCLC patients who were treated between February 2021 and November 2024 were analyzed. Before nivolumab treatment, inflammatory markers such as neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), lymphocyte-to-monocyte ratio (LMR), systemic immune-inflammation index (SII), systemic inflammation response index (SIRI), prognostic nutritional index (PNI), hemoglobin-albumin-lymphocyte-platelet score (HALP), neutrophil-to-eosinophil ratio (NER) and C-reactive protein-to-albumin ratio (CAR) were calculated. Factors affecting overall survival (OS) were determined by Cox regression analysis, and ROC curve analysis was used to calculate the ideal cut-off.
Results
The study included 229 NSCLC patients and the median age of the patients was 63 years. The majority were male (84.3%) and had right lung localization (56.8%). Median overall survival was calculated as 21.2 months (95% CI: 17.4-25.0). In univariate cox-regression analysis, the presence of brain metastases (HR: 2.08; p=0.004), liver metastases (HR: 1.85; p=0.014) and adrenal metastases (HR: 1.64; p=0.045) negatively affected the treatment response. Inflammatory markers such as high NLR (HR: 2.04; p
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medical Oncology, Ankara Etlik City Hospital, Ankara, Turkey.
- Department of Medical Oncology, Nevşehir State Hospital, Nevşehir, Turkey.
- Department of Medical Oncology, Ankara Atatürk Sanatoryum Training and Research Hospital, Ankara, Turkey.
ORCID-Profile: Esra Zeynelgil, Dilek Çağlayan, Hayriye Şahinli, Tülay Eren
Zitieren
APA
Zeynelgil, E., Çağlayan, D., Çelik, S., Ayyıldız Sevim, H., Şahinli, H., Karakaya, S., & Eren, T. (2025). Do Inflammatory and Nutritional Markers Predict Prognosis in Metastatic Non-Small Cell Lung Cancer Patients Receiving Nivolumab. Journal of Inflammation Research, Volume 18, 15283-15292. https://doi.org/10.2147/jir.s541842
Vancouver
Zeynelgil E, Çağlayan D, Çelik S, Ayyıldız Sevim H, Şahinli H, Karakaya S, et al. Do Inflammatory and Nutritional Markers Predict Prognosis in Metastatic Non-Small Cell Lung Cancer Patients Receiving Nivolumab. Journal of Inflammation Research. 2025;Volume 18:15283-15292. doi:10.2147/jir.s541842
BibTeX
@article{Zeynelgil2025,
author = {Zeynelgil, Esra and Çağlayan, Dilek and Çelik, Selahattin and Ayyıldız Sevim, Hatice and Şahinli, Hayriye and Karakaya, Serdar and Eren, Tülay},
title = {Do Inflammatory and Nutritional Markers Predict Prognosis in Metastatic Non-Small Cell Lung Cancer Patients Receiving Nivolumab},
journal = {Journal of Inflammation Research},
year = {2025},
volume = {Volume 18},
pages = {15283--15292},
doi = {10.2147/jir.s541842}
}
EUVIMED